Chris Parker

25.8k total citations · 5 hit papers
245 papers, 11.2k citations indexed

About

Chris Parker is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Chris Parker has authored 245 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Pulmonary and Respiratory Medicine, 112 papers in Radiology, Nuclear Medicine and Imaging and 53 papers in Oncology. Recurrent topics in Chris Parker's work include Prostate Cancer Treatment and Research (185 papers), Prostate Cancer Diagnosis and Treatment (103 papers) and Radiopharmaceutical Chemistry and Applications (86 papers). Chris Parker is often cited by papers focused on Prostate Cancer Treatment and Research (185 papers), Prostate Cancer Diagnosis and Treatment (103 papers) and Radiopharmaceutical Chemistry and Applications (86 papers). Chris Parker collaborates with scholars based in United Kingdom, United States and Canada. Chris Parker's co-authors include Alan Horwich, David P. Dearnaley, Mark Emberton, Hashim U. Ahmed, Richard Kaplan, Louise Brown, Rhian Gabe, Richard Hindley, Ahmed El‐Shater Bosaily and Mahesh Parmar and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Chris Parker

240 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

2017 2.2k citations Louise Brown, Mahesh Parmar et al. profile →
Prostate cancer

2015 708 citations Chris Parker, Rosalind A. Eeles et al. profile →
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 577 citations Chris Parker, Axel Heidenreich et al. Annals of Oncology profile →
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010 487 citations Alan Horwich, Chris Parker et al. Annals of Oncology profile →
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2015 297 citations Chris Parker, Silke Gillessen et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Chris Parker

Since Specialization

Citations

This map shows the geographic impact of Chris Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Parker more than expected).

Fields of papers citing papers by Chris Parker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Parker. The network helps show where Chris Parker may publish in the future.

Co-authorship network of co-authors of Chris Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Parker. A scholar is included among the top collaborators of Chris Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Parker. Chris Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sustainability and affordability of building electrification: A state-by-state holistic approach for multifamily buildings 2024 ·Sustainable Cities and Society ·(unknown), Chris Parker, (unknown), (unknown), Kody M. Powell	1
2	Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial 2024 ·Clinical Oncology ·Priyanka Patel, (unknown), Alison Reid, Chris Parker, Julia Murray, Angela Pathmanathan, (unknown), (unknown), Yae‐Eun Suh, J. Frew, (unknown), Isabel Syndikus, (unknown), Nina Tunariu, Alison Tree	2
3	Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047) 2024 ·European Urology ·Chris Parker, Noel W. Clarke, Adrian Cook, René Horsleben Petersen, Charles Catton, William Cross, Howard Kynaston, Raj Persad, Fred Saad, John Logue, Heather Payne, Claire Amos, L. Bower, Rakesh Raman, Ian Sayers, Jane Worlding, Wendy R. Parulekar, Mahesh Parmar, Matthew R. Sydes	5
4	1782P Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1\|RT comparison 2023 ·Annals of Oncology ·(unknown), (unknown), Laura Murphy, Macey L. Murray, Louise Brown, Max Parmar, Nicholas D. James, Chris Parker, Matthew R. Sydes, Nigel Clarke, Ashwin Sachdeva	4
5	Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response 2023 ·JNCI Cancer Spectrum ·Chris Parker, Nina Tunariu, Holly Tovey, Roberto Alonzi, Matthew Blackledge, Gary Cook, Sue Chua, Yong Du, S. Hafeez, Iain Murray, Anwar R. Padhani, John Staffurth, Alison Tree, (unknown), (unknown), Andra Curcean, Peter Chatfield, Sophie Perry, Dow‐Mu Koh, Emma Hall	3
6	637P The prognostic value of the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223): A post-hoc analysis of the ALSYMPCA phase-III trial 2020 ·Annals of Oncology ·Alexander Meisel, Chris Parker, (unknown), Oliver Sartor, Frank Stenner	2
7	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer 2019 ·Journal of Clinical Oncology ·James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris Parker, David Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Fred Saad, Neal D. Shore, Liddy Chen, Christopher R. Heery, Winald R. Gerritsen, Frank Priou, Niels Christian Langkilde, (unknown), Philip W. Kantoff	183
8	A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy 2019 ·Journal of Personalized Medicine ·Jan Verbeek, Daan Nieboer, Chris Parker, Michael W. Kattan, Ewout W. Steyerberg, Monique J. Roobol	1
9	Patterns of recurrence after prostate bed radiotherapy 2019 ·Radiotherapy and Oncology ·Douglas Brand, (unknown), David P. Dearnaley, Rosalind A. Eeles, Robert Huddart, Vincent Khoo, Julia Murray, Yae‐Eun Suh, Alison Tree, Nicholas van As, Chris Parker	15
10	Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer 2018 ·Clinical and Translational Radiation Oncology ·Anna Wilkins, (unknown), Shama Hassan, Claire Blanchard, Clare Cruickshank, Clare Griffin, (unknown), Catherine M. Corbishley, Chris Parker, David P. Dearnaley, Emma Hall	1
11	ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC) 2018 ·Annals of Oncology ·Mitchell R. Smith, Chris Parker, Fred Saad, K. Miller, Bertrand Tombal, Quan Sing Ng, Martin Bögemann, В. Б. Матвеев, Josep M. Piulats, Luis Eduardo Rosa Zucca, Axel Heidenreich, Yoshiyuki Kakehi, (unknown), Heiko Krissel, Jiayu Shen, (unknown), Celestia S. Higano	9
12	appendix 8: Prostate cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Genitourinary-Cancers) 2016 ·Annals of Oncology ·Chris Parker, Silke Gillessen, Alan Horwich	1
13	Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up breakdown → 2015 ·Annals of Oncology ·Chris Parker, Silke Gillessen, Axel Heidenreich, Alan Horwich	297
14	Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases 2013 ·European Journal of Cancer ·Chris Parker, Daniel Heinrich, David Bottomley, Peter Hoskin, Lars Franzén, A. Solberg, (unknown), Jonathan Reuning‐Scherer, C. Gillies O'Bryan-Tear, Sten Nilsson	2
15	Radium-223 Dichloride (Ra-223) Impact on Skeletal-Related Events, External Beam Radiation Therapy (EBRT), and Pain in Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases: Updated Results From the Phase 3 ALSYMPCA Trial 2013 ·International Journal of Radiation OncologyBiologyPhysics ·Jeff M. Michalski, Oliver Sartor, Chris Parker, Minghua Shan, J. Garcia‐Vargas, A. Aksnes, Nicholas J. Vogelzang	3
16	Frequency of Screening Magnetic Resonance Imaging to Detect Occult Spinal Cord Compromise and to Prevent Neurological Deficit in Metastatic Castration-resistant Prostate Cancer 2010 ·Clinical Oncology ·(unknown), S.A. Sohaib, Yolanda Barbáchano, Chris Parker, Robert Huddart, Alan Horwich, David P. Dearnaley	16
17	Treatment of early prostate cancer: active surveillance 2009 ·(unknown), Chris Parker	2
18	Clinical implications of introducing a new PSA assay 2008 ·International Urology and Nephrology ·Ramachandran Venkitaraman, A. Norman, (unknown), David P. Dearnaley, Alan Horwich, Robert Huddart, Chris Parker	5
19	Testosterone and erectile function recovery after radiotherapy and long‐term androgen deprivation with luteinizing hormone‐releasing hormone agonists 2006 ·British Journal of Urology ·Derek Wilke, Chris Parker, (unknown), (unknown), Charles Catton, Mary Gospodarowicz, Padraig Warde	39
20	Does age influence the behaviour of localized prostate cancer? 2001 ·British Journal of Urology ·Chris Parker, Mary Gospodarowicz, Padraig Warde	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact